Name
AstraZeneca Oncology Late Development Pipeline Overview
Speakers
Executive Advisory Board (EAB) or Platinum Sponsor
EAB - Astra Zeneca
Content Presented on Behalf of
Executive Advisory Board (EAB)
Services/Agencies represented
Executive Advisory Board (EAB)
Session Type
Breakout
Date
Tuesday, March 4, 2025
Start Time
4:30 PM
End Time
5:30 PM
Room#/Location
Baltimore 1-2
Focus Areas/Topics
Clinical Care, Trending/Hot Topics or Other not listed
Learning Outcomes
Following this session, the attendee will be able to:
1. Understand AstraZeneca Oncology priority therapeutic areas for clinical development
2. Understand AstraZeneca Oncology recent data releases and future directions in the areas of prostate cancer and hematologic malignancies
3. Explain areas of interest for collaboration between AstraZeneca and Veterans Affairs health care system and oncology programs
1. Understand AstraZeneca Oncology priority therapeutic areas for clinical development
2. Understand AstraZeneca Oncology recent data releases and future directions in the areas of prostate cancer and hematologic malignancies
3. Explain areas of interest for collaboration between AstraZeneca and Veterans Affairs health care system and oncology programs
CE/CME Session
Non-CE Session
Session Currently Live
Description
Review AstraZeneca Oncology priority therapeutic areas with a particular spotlight on prostate and hematology therapeutic areas, future directions for registered products and late-phase new molecular entities, and discuss areas of interest for collaboration.